Novel vaccines: Bridging research, development and production

Expert Review of Vaccines

Volumn 7, Issue 9, 2008, Pages 1321-1324

  Demirjian, Alicia ^a   Levy, Ofer ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACAM529 VACCINE; ADJUVANT; ANTHRAX VACCINE; BIOMATERIAL; DNA VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HERPES SIMPLEX VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 18; MALARIA VACCINE; NEUTRALIZING ANTIBODY; ORAL POLIOMYELITIS VACCINE; POLYGLACTIN; TOLL LIKE RECEPTOR 2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VACCINE;

ANTIBACTERIAL ACTIVITY; ANTIGEN PRESENTING CELL; CONFERENCE PAPER; CYTOKINE PRODUCTION; DRUG APPROVAL; DRUG SAFETY; ELECTROPORATION; EMULSION; FOOD AND DRUG ADMINISTRATION; GENITAL HERPES; GUINEA PIG; HERPES SIMPLEX VIRUS; HUMAN; IMMUNOGENICITY; MALARIA; MOUSE; NANOEMULSION; NONHUMAN; NOROVIRUS; PLASMODIUM; POLIOMYELITIS; PRIORITY JOURNAL; VACCINE PRODUCTION;

ADJUVANTS, IMMUNOLOGIC; ANTIGEN-PRESENTING CELLS; COMMUNICABLE DISEASE CONTROL; HUMANS; NANOPARTICLES; VACCINES; VACCINES, DNA;

EID: 55849150142     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.7.9.1321     Document Type: Conference Paper

References (15)

1. Vignuzzi, M, Wendt E, Andino R. Engineering attenuated virus vaccines by controlling replication fidelity. Nat. Med. 14(2), 154-161 (2008).
2. Sacarlal J, Aponte JJ, Aide P et al. Safety of the RTS,S/AS02A malaria vaccine in Mozambican children during a Phase IIb trial. Vaccine 26(2), 174-184 (2008).
3. Stewart VA, McGrath SM, Dubois PM et al. Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared with that with either malaria vaccine alone. Infect. Immun. 75(5), 2283-2290 (2007).
4. Yan M, Roehrl MH, Basar E, Wang JY et al. Selection and evaluation of the immunogenicity of protective antigen mutants as anthrax vaccine candidates. Vaccine 26(7), 947-955 (2008).
5. Hoshino Y, Dalai SK, Wang K et al. Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs. J. Virol. 79(1), 410-418 (2005).
6. van Lint AL, Torres-Lopez E, Knipe DM. Immunization with a replication-defective herpes simplex virus 2 mutant reduces herpes simplex virus 1 infection and prevents ocular disease. Virology 368(2), 227-231 (2007).
7. Eisenbarth SC, Colegio OR, O'Connor W, Sutterwala FS, Flavell RA. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 453(7198), 1122-1126 (2008).
8. Latz E, Franko J, Golenbock DT, Schreiber JR. Haemophilus influenzae type b-outer membrane protein complex glycoconjugate vaccine induces cytokine production by engaging human Toll-like receptor 2 (TLR2) and requires the presence of TLR2 for optimal immunogenicity. J. Immunol. 172(4), 2431-2438 (2004).
9. van Duin D, Medzhitov R, Shaw AC. Triggering TLR signaling in vaccination. Trends Immunol. 27(1), 49-55 (2006).
10. Levy O, Suter EE, Miller RL, Wessels MR. Unique efficacy of Toll-like receptor 8 agonists in activating human neonatal antigen-presenting cells. Blood 108, 1284-1290 (2006).
11. Philbin VJ, Levy O. Immunostimulatory activity of Toll-like receptor 8 agonists towards human leucocytes: basic mechanisms and translational opportunities. Biochem. Soc. Trans. 35(Pt 6), 1485-1491 (2007).
12. Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat. Rev. Drug Discov. 5(6), 471-484 (2006).
13. Steenblock ER, Fahmy TM. A comprehensive platform for ex vivo T-cell expansion based on biodegradable polymeric artificial antigen-presenting cells. Mol. Ther. 16(4), 765-772 (2008).
14. Makidon PE, Bielinska AU, Nigavekar SS et al. Pre-clinical evaluation of a novel nanoemulsion-based hepatitis B mucosal vaccine. PLoS ONE 3(8), e2954 (2008).
15. US FDA: vaccine produce approval process www.fda.gov/cber/vaccine/ vacappr.htm